ABOUT US

Programmable gene silencing to transform advanced therapies

What we do

Laverock’s technology allows the development of powerful, novel therapeutic approaches that are not possible with existing technologies. We seek to address significant challenges by making advanced therapies more effective, safer and more accessible.

Our origins

Laverock has an exclusive worldwide licence for the innovative, proprietary GEiGS® technology for use in human cells and has built on this base to advance its potential for therapeutic development. We are based at the Stevenage Bioscience Catalyst, a leading hub for cell and gene therapy companies.

Our culture

We are building a world-class team of scientific experts and professionals. People are central to everything we do and we strive to ensure a dynamic, inclusive and collaborative work environment. We understand the journey we are on will require collaboration not only internally, but also with likeminded organisations and partners. 

Sustainability

Laverock's core goals are closely aligned with our environmental, social and governance standards, allowing us to adopt a sustainability mindset as part of the company’s foundational values.


We are committed to driving down our energy and carbon footprint and seek to promote strong oversight, transparency and risk management at all levels of our organisation, ensuring the resilience and long-term preservation of value for our business.

Gene editing induced gene silencing (GEiGS) uses universal gene editing tools such as CRISPR, to minimally edit the host’s own non-coding genes and redirect their silencing activity (RNAi) towards any desired target gene or gene family.

Our cutting edge bioinformatics platform designs gene editing solutions to allow precise and effective implementation of GEiGS ® technology, ensuring desired cell type or condition-specific activity. 

GEiGS® targets endogenous or exogenous genes 

Stable, Tunable and Programmable gene silencing functionality 

By redirecting the silencing activity of the host’s own non-coding genes, GEiGS ® introduces novel RNAi activity with significant advantages over other approaches. GEiGS requires only minimal changes to the host’s genome, thus avoiding epigenetic silencing mechanisms and allowing for highly stable RNAi activity over time and across generations. Silencing activity is tuned via both non-coding RNA selection and controlling sequence complementarity and utilises the cells native regulatory machinery to achieve programmable functionality.

Compatible with allogeneic, iPSC-derived product development

Editing of non-coding genes is carried out at the iPSC stage, allowing efficient gene editing workflows and assessment of off-target profiles and avoiding limitations associated with autologous products and associated cost-of-good, regulatory and scalability challenges.

Attractive regulatory profile 

In contrast to many other cell engineering approaches seen in the cell therapy products, gene modifications used are minimal and do not require stable incorporation of non-human sequences.

Universal platform that works with existing gene editing tools 

GEiGS ® is not dependent on any one specific gene editing tool, but instead can be deployed by using a broad range of different nucleases. This provides us with freedom to choose which gene editing tools to implement GEiGS® edits based on the specific project, application and targeting requirements.